Technische Universität München

Test predicts outcome of hay fever therapies

TECHNICAL UNIVERSITY OF MUNICH

Corporate Communications Center

phone: +49 89 289 22731 - email: presse@tum.de - web: www.tum.de

This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/detail/article/35000/

NEWS RELEASE

Test predicts outcome of hay fever therapies

Allergy researchers look into molecular processes in hyposensitization to pollen

Allergen-specific immunotherapy can make everyday life much more pleasant for allergy sufferers and provide long-term protection against asthma. It is unclear, however, what exactly happens during this treatment. A team at the Technical University of Munich (TUM) and Helmholtz Zentrum München investigated the processes taking place in the body over the course of a three-year allergen-specific immunotherapy. The researchers found clues as to why the allergy immunization takes so long and how the chances of success can be determined at a very early stage.

In allergen-specific immunotherapy - once known as hyposensitization - doctors inject patients with the substances that cause allergic reactions, mostly pollen or mite allergen extracts. In the first phase of the therapy, the dose is gradually increased. Once a so-called maintenance dose is reached, the patient receives injections at that dosage over an extended period - generally three years. If all goes well, there is lasting reduction in the intensity of allergic reactions after the treatment is completed.

It is still unclear what exactly happens in the body during these treatments. A team surrounding Dr. Adam Chaker, the head of the Allergy Outpatient Clinic at the Clinic and Polyclinic for Ear, Nose and Throat Medicine at the the TUM rechts der Isar University Hospital and Professor Carsten Schmidt-Weber, head of the Center for Allergies and the Environment (ZAUM) of TUM and the Helmholtz Zentrum München, has now completed the first investigation of the complex interplay of various cell types and substances of the human immune system over the course of a three-year immunotherapy treatment.

Many different immune cells involved

In the past, allergy research has focused particularly on the role of various types of T cells.According to this - albeit highly simplified - model, pro-allergic T cells (Th2 and Th17 cells) heighten the allergic responses in the body when they encounter certain substances. Regulatory T cells (T regs), by contrast, inhibit the response to an allergen.

"Our data show that the bodily processes during immunotherapy are far more complex than once believed," says Adam Chaker. "They involve cell types that have previously received very little attention in this context. In particular, we are convinced that regulatory B cells play a much more important role than we once thought."

Test shows: the second therapy phase is not a game of chance

"In the second treatment phase, the body's immune system decides whether to continue launching all-out attacks on an allergen, resulting in hay fever, asthma or other allergic conditions, or whether the body will learn to tolerate the allergen," explains Adam Chaker. The ratios of pro-allergic T cells, T regs and regulatory B-cells undergo constant change during that time. Over the course of the study, there were repeated shifts in which of the cell types was most numerous, also depending on pollen counts and other factors, with different types more prevalent at various times. It was only after around three years that the ratios gradually stabilized.

However, this phase is anything but a game of chance. In the patients who completed the treatment as planned, there were common factors that made it possible to forecast the success of the therapy at an early stage. If a lot more regulatory B-cells and a lot fewer TH-17 cells are counted immediately after the first phase, i.e. the introductory treatment phase, a significant decrease in allergy symptoms was seen after three years.

Good reasons for seeing the treatment through

"We have patented this test," says Adam Chaker. "If we can develop it to the point where it can go into full production, we could save patients from going through expensive and time-consuming treatments with little chance of success. But in case of a positive test result, there are good reasons for seeing a three-year therapy through to the end. In the past, people have tended to give up before finishing."

In addition, a better understanding of the molecular mechanisms could serve as the basis for more effective treatments. To do that, however, it will be necessary to confirm the results of the current study through additional investigations and find out more about the mechanisms involved, says Adam Chaker.

Publication:

U.M. Zissler, C.A. Jakwerth, F.M. Guerth, L. Pechtold, J.A. Aguilar-Pimentel, K. Dietz, K. Suttner, G. Piontek, B. Haller, Z. Hajdu, M. Schiemann, C.B. Schmidt-Weber, A.M. Chaker. Early IL-10 producing B-cells and coinciding Th/Tr17 shifts during three year grass-pollen AIT. EBioMedicine (2018) DOI:10.1016/j.ebiom.2018.09.016 (Open Access)

More Information:

Center for Allergies and the Environment (ZAUM)

- www.zaum-online.de
- Clinic and Polyclinic for Ear, Nose and Throat Medicine www.hno.mri.tum.de   

Contact:

PD Dr. Adam M. Chaker

Technical University of Munich

Klinikum rechts der Isar

Clinic and Polyclinic for Ear, Nose and Throat Medicine and

Center for Allergies and the Environment (ZAUM)

Tel: +49 89 4140 2370

adam.chaker@tum.de

The Technical University of Munich (TUM) is one of Europe's leading research
universities, with around 550 professors, 42,000 students, and 10,000 academic
and non-academic staff. Its focus areas are the engineering sciences, natural
sciences, life sciences and medicine, combined with economic and social
sciences. TUM acts as an entrepreneurial university that promotes talents and
creates value for society. In that it profits from having strong partners in
science and industry. It is represented worldwide with the TUM Asia campus in
Singapore as well as offices in Beijing, Brussels, Cairo, Mumbai, San Francisco,
and São Paulo. Nobel Prize winners and inventors such as Rudolf Diesel, Carl von
Linde, and Rudolf Mößbauer have done research at TUM. In 2006 and 2012 it won
recognition as a German "Excellence University." In international rankings, TUM
regularly places among the best universities in Germany. 



Additional press releases: Technische Universität München

You might also be interested in: